In Brief This Week: Ariosa Diagnostics; Abbott; Quidel; Precision BioSciences, Cellectis; Vermillion; Rosetta Genomics; BGI; NeoGenomics; Warnex; ClearBridge BioMedics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariosa Diagnostics, formerly known as Aria Diagnostics, said this week that it has completed clinical validation of its Harmony Prenatal Test for non-invasive detection of common fetal trisomies and announced the first medical facility to offer the test. The San Jose, Calif.-based firm said that Atlanta Perinatal Consultants at Northside Hospital in Atlanta is the first to offer the test, which will "become more broadly available in the near future."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.